Allow Medicare and Medicaid to negotiate lower prescription drug prices.

Val T. Hoyle · Oregon · Democratic

policy impact 79.00 specificity 76.00 extraction confidence 9800%

Contest this claim

Occurrences

Finally allowing Medicaid and Medicare to bargain with Big Pharma on prescription costs, and ensuring those savings are available to all Americans.

Commits to drug-price negotiation through Medicare and Medicaid.

Priorities | Val Hoyle for Congress
campaign · campaign_site · model gpt-5.4-mini

Finalmente, permitir que Medicaid y Medicare negocien con las grandes compañías de medicamentos sobre los costos de estos y así garantizar que esos ahorros estén disponibles para todos los estadounidenses.

Supports giving Medicare and Medicaid negotiation power to lower drug prices.

Prioridades | Val Hoyle por el Congreso
campaign · campaign_site · model gpt-5.4-mini

Val’s healthcare priorities include finally allowing Medicaid and Medicare to bargain with Big Pharma on prescription costs, and ensuring those savings are available to all Americans.

Commitment to let Medicare and Medicaid negotiate drug prices.

Priorities | Val Hoyle for Congress
campaign · other · model gpt-5.4-mini

Evidence

CMS says the selected-drugs file tracks negotiated maximum fair prices, is updated annually, and that on March 13, 2026 all 15 drugs chosen for the third Medicare negotiation cycle had agreed to participate; any negotiated prices would take effect in 2028.

Recent CMS implementation confirms Medicare drug-price negotiation is active and producing lower-price authority, but this only addresses the Medicare side of the broader promise.

partial unknown

Selected Drugs and Negotiated Prices | CMS
secondary · model gpt-5.4-mini · confidence 97%

Contest this evidence item

CMS states that the Medicaid Drug Rebate Program includes CMS, state Medicaid agencies, and manufacturers, covers outpatient drugs in all 50 states and D.C., and requires manufacturers to pay rebates to states that offset Medicaid drug costs.

Medicaid already has a federal rebate mechanism that lowers outpatient drug costs, but the page does not show a new Medicare-style negotiation program for Medicaid.

partial unknown

Medicaid Drug Rebate Program (MDRP) | Medicaid
secondary · model gpt-5.4-mini · confidence 93%

Contest this evidence item

Assessments

partial unknown

Hoyle’s own campaign priorities page promised to let both Medicare and Medicaid bargain over drug prices. The Medicare side is substantially real at the federal level: CMS says the Inflation Reduction Act signed in August 2022 gave Medicare direct negotiation authority, with negotiated prices taking effect starting January 1, 2026 and later cycles underway. But the Medicaid side is not shown as newly delivered here; Medicaid.gov describes the longstanding Medicaid Drug Rebate Program, which lowers costs through rebate agreements, not a new broad Medicare-style negotiation program for Medicaid. Candidate credit is also limited: Hoyle’s House biography says she was sworn into Congress in January 2023, after the 2022 law creating Medicare negotiation had already passed, and her House health page points to a different drug-pricing bill she introduced rather than the law that created Medicare negotiation. That supports partial credit, not full delivery.

provider codex_cli · model gpt-5.4 · confidence 92%